Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) has reached the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG, securing a USD $1 million payment. The agreement, dated February 10, 2026, supports a feasibility study for producing pharmaceutical-grade iodine from produced water in the Anadarko Basin. The company's Houston R&D team successfully proved its proprietary Mueller iodine extraction process, achieving 99.8% purity iodine in laboratory tests, which provided the technical confirmation needed for Bayer to advance the program.
The transportable pilot plant is nearing completion and is scheduled for field operation this fall. With this milestone, Voyageur has received USD $1,350,000 of the USD $2,350,000 committed by Bayer. The remaining USD $1,000,000 Milestone Payment II will be released upon completion of the FEL-3 feasibility study, which will be conducted with engineering support from Fluor Corporation. This non-dilutive funding is expected to accelerate Voyageur's iodine supply strategy, moving closer to validating a reliable North American source of high-purity iodine for contrast media drugs.
Brent Willis, President and CEO of Voyageur, emphasized the importance of this progress: “Achievement of this first milestone under our agreement with Bayer is an important step forward for Voyageur. It confirms that the feasibility work is advancing as planned and triggers the first major non-dilutive payment under the collaboration. This capital is expected to further accelerate our iodine supply strategy and move us closer to validating a reliable North American source of high-purity iodine for use in contrast media drugs.”
Subject to successful completion of the feasibility study, Bayer and Voyageur may consider a second phase, including a long-term offtake supply agreement. The project proposes a staged production rollout, beginning with 200 tonnes per year, with potential expansion to 1,000 tonnes per year. Central manufacturing would process iodine concentrate into USP pharmaceutical-grade iodine for contrast drug production.
The global contrast media market is estimated at approximately USD $7.06 billion, and Voyageur's vertically integrated strategy aims to improve supply-chain security, reduce reliance on imported raw materials, and lower operating costs. The company also owns a 100% interest in the Frances Creek barium sulfate project, which is central to its plans to become the first vertically integrated company in the radiology contrast media drug market.
Fluor Corporation has been providing engineering, thermodynamic modeling, and project planning support. Subsequent engineering phases will progress through FEL-2 (Concept Design) and FEL-3 (Basic Design), with FEL-2 expected to take four to five months and FEL-3 seven to nine months, refining cost estimates and design details.
Willis added: “Voyageur is focused on building multiple potential revenue streams through a staged commercialization strategy. This includes near-term opportunities from barium contrast sales, iodine sales under the Bayer collaboration, and longer-term opportunities from barium and iodine-based contrast drug sales. The Bayer collaboration, combined with technical support from Fluor, continues to strengthen the foundation for scalable domestic iodine production.”
